Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Scope of Analysis

The Need for Inhalation Biologics Formulation

Inhalation Drug Delivery—Introduction

Segmentation—Formulations for Drug Inhalation

Pros and Cons of Formulation and Drug Delivery Systems for Inhalation

Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics

Promising Inhalation Therapy—Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines

Growth Drivers

Growth Restraints

Pipeline Analysis of Inhaled Vaccines and mAbs

Vaccines and mAbs under Clinical Development

Primary Technologies—AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)

Primary Technologies—Nanoemulsion Platform (Intranasal Adjuvant Technology)

R&D Trends

Collaboration and Partnership Trends

Funding and Investment Analysis

Patent Analysis

Future Roadmap

Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution

Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution (continued)

Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services

Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services (continued)

Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration

Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration (continued)

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer